The Advanced Prostate Cancer Consensus Conference

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304). Enzalutamide significantly improves overall survival (OS) of patients with metastatic hormone- sensitive prostate cancer (mHSPC). However, ∼10% of patients will die within 2 years. PCPro is a plasma l...

Association of the circulating lipid panel, PCPro, with clinical outcomes
www.annalsofoncology.org/article/S092...

post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk

jamanetwork.com/journals/jam...

The field continues to evolve with the development of novel therapeutic agents, broader clinical indications, and deeper integration of nuclear imaging w/ tx

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After D... Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radioligands has an established role in the assessment of recurrence…

Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence & Distant Metastases in Biochemical Recurrence of #ProstateCancer After Definitive Treatment

www.sciencedirect.com/science/arti...

Findings underscore importance of PSA stratification

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study

annalsofoncology.org/article/S092...

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy This nonrandomized clinical trial evaluates physician-reported late toxic effects and 2-year patient-reported outcomes following post–radical prostatectomy stereotactic body radiotherapy.

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy

jamanetwork.com/journals/jam...

findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT
#ProstateCancer

@silkegillessen.bsky.social 🚨

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International M... We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised…

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography #ProstateCancer Molecular Imaging Standardized Evaluation (PPP2)

www.sciencedirect.com/science/arti...

PPP2 offers a robust tool for 3- and 5-year survival prediction

Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial To our knowledge, this is the first randomised trial for metachronous PET-detected nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination with 6 months of androgen de...

PEACE V–STORM: Salvage metastasis-directed therapy versus elective nodal radiotherapy☢️for oligorecurrent nodal #ProstateCancer metastases out on Lancet Oncology

www.thelancet.com/journals/lan...

Findings suggest ENRT may be a promising standard approach pending confirmation in a phase 3 trial.

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
@ascocancer.bsky.social Update

ascopubs.org/doi/full/10....

Updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer

Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer

aacrjournals.org/cancerres/ar...

Findings highlight promise of this integrative approach for developing non-invasive, clinically feasible diagnostic tools.

Racial disparities in #ProstateCancer in the UK and the USA

nature.com/articles/s41...

paper emphasizes that addressing these inequities requires systemic change: dismantling structural racism, increasing representation in clinical research and healthcare workforce

@silkegillessen.bsky.social

Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy 177Lu-rhPSMA-10.1 is a novel radiohybrid prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy for prostate cancer. We conducted preclinical analyses on non–tumor-bearing BALB...

Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for #ProstateCancer

jnm.snmjournals.org/content/66/4...

These findings support its potential as a next-generation PSMA-targeted therapy with improved tumor-to-kidney uptake ratios and enhanced antitumor activity.

Targeting the tumour cell surface in advanced prostate cancer - Nature Reviews Urology This Review provides an overview of the main targetable surface proteins in prostate cancer, defined as the surfaceome, discussing the mechanisms of action and efficacy of currently available drugs ta...

Targeting the tumour cell surface in advanced prostate cancer out on nature reviews urology

www.nature.com/articles/s41...

A deeper understanding of the dynamic nature of these targets could also inform future combination strategies.

FDA expands Pluvicto’s prostate cancer indication On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication

www.fda.gov/drugs/resour...

FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI

Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis This randomized, noninferiority trial of biopsy-naive men compares the detection of Gleason Grade Group ≥2 prostate cancer using microultrasonography-guided and MRI fusion-guided biopsy.

Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial

jamanetwork.com/journals/jam...

These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer In this post-hoc analysis of a phase 3 randomized controlled trial comparing apalutamide versus placebo in metastatic castration-sensitive prostate cancer, patients with two or less bone metastases h...

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive #ProstateCancer (TITAN)

acsjournals.onlinelibrary.wiley.com/doi/full/10....

findings suggest that baseline bone metastasis count may help identify optimal candidates for apalutamide tx in mCSPC.

Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium Trials comparing moderately hypofractionated radiotherapy (MHFRT) to conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied c…

Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium

sciencedirect.com/science/arti...

Finds that isodose regimens, like 60 Gy in 20 fractions, are recommended as the standard for localized #ProstateCancer

Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial

t.co/tzTr4MmoZi

TRAP Results showed a median progression-free survival (PFS) of 6.4 months, with 39% of patients maintaining PFS beyond 12 months.

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk

jamanetwork.com/journals/jam...

Study suggests extending PSA assessment to at least 3 months post-RP to minimize overtreatment

@barbaramelao.bsky.social
@yukselurun.bsky.social

Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy

jnm.snmjournals.org/content/66/3...

The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. #ProstateCancer

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)... Prostate Cancer and Prostatic Diseases - Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A...

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment.

www.nature.com/articles/s41...

Results suggest that SBRT may be a viable option for treating omCRPC after progression compared to systemic therapy

The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY

aacrjournals.org/cancerdiscov...

The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer

Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in…

Heterogeneity of the Treatment Effect w/ PARP Inhibitors in Metastatic Castration-resistant #ProstateCancer

sciencedirect.com/science/arti...

Overall, BRCA alterations confer the most substantial survival benefit, while minimal or no benefits were observed in patients with ATM or CHEK2 alterations

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A | JCO Oncology Practice

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant #ProstateCancer

ascopubs.org/doi/pdf/10.1...

The update is based on a trial by Sartor et al., which showed improved PFS and OS in patients with PSMA-positive mCRPC after a median follow-up of 20.9 months.

YouTube video by OncoAlert 360 Oncology Here & Now Podcast: Prostate Cancer & APCCC with Drs. Silke Gillessen & Aurelius Omlin

Oncology Here & Now🎙️

We interview Drs. @silkegillessen.bsky.social 🇨🇭& @aureliusomlin.bsky.social 🇨🇭and delve into Topics & evolution of Advanced #ProstateCancer Consensus Conference @apccc.bsky.social

@barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

youtu.be/Pxzzecwqqkk?...

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men W/ Suspected #ProstateCancer

jamanetwork.com/journals/jam...

Study finds men w/ negative MRI who avoided biopsy were not at increased risk of csPCa, supporting safety of an MRI-1st diagnostic approach when combined with systematic FU

Functional outcomes after primary vs delayed robot-assisted radical prostatectomy following active surveillance AbstractBackground. It is unknown if a period of active surveillance before prostatectomy for prostate cancer (PCa) worsens functional outcomes. The aim of

Functional outcomes after primary vs delayed robot-assisted radical prostatectomy following active surveillance

academic.oup.com/jncics/advan...

Suggest active surveillance doesntt have significant detrimental effect on functional outcomes, supportin for men w/low & favorable intermediate-risk PCa

Prostate Cancer Mortality in Men Aged 70 Years After Recent PSA Screening This cohort study examines prostate cancer–specific mortality and metastatic prostate cancer risks after age 70 in men who had undergone recent prostate-specific antigen (PSA) screening.

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening

jamanetwork.com/journals/jam...

Findings suggest that continuing PSA screening in older men may be unnecessary for those with low PSA values before age 70. #ProstateCancer

Trends in Prostate Cancer Incidence and Mortality Rates This cohort study examines the trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region of California.

Trends in #ProstateCancer Incidence and Mortality Rates Out on JAMA Network

jamanetwork.com/journals/jam...

Findings underscore need for improved prostate cancer screening strategies to address the rising incidence of distant-stage disease

Ping
@yukselurun.bsky.social
@barbaramelao.bsky.social

Genetic testing in prostate cancer management: Considerations informing primary care Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may be associated with aggressive disease and poorer outcomes, and can have hereditary cancer implications fo...

Genetic testing in prostate cancer management: Considerations informing primary care

acsjournals.onlinelibrary.wiley.com/doi/10.3322/...

Review discusses the role of genetic testing in personalized PC care, the need for comprehensive family histories, and the integration of genetic counseling

Is there a role of PSMA-PET in focal therapy planning and follow-up? - Prostate Cancer and Prostatic Diseases Prostate Cancer and Prostatic Diseases - Is there a role of PSMA-PET in focal therapy planning and follow-up?

Is there a role of PSMA-PET in focal therapy planning and follow-up? A Review out on Prostate Cancer

www.nature.com/articles/s41...

Systematic review aims to summarize current applications of PSMA-PET in FT and its future perspectives.

@oncoalert.bsky.social 🚨
@barbaramelao.bsky.social